Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 6/20 | 0.98 |
| ▸ | NR3C1 | P04150 | 5/20 | 0.98 |
| ▸ | SMN1; SMN2 | Q16637 | 5/20 | 0.98 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.98 |
| ▸ | PGR | P06401 | 4/20 | 0.98 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.98 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.98 |
| ▸ | MAPT | P10636 | 3/20 | 0.98 |
| ▸ | MEN1 | O00255 | 2/20 | 0.98 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.98 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.98 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.98 |
| ▸ | HPGD | P15428 | 1/20 | 0.98 |
| ▸ | MLNR | O43193 | 1/20 | 0.98 |
| ▸ | NR1I2 | O75469 | 1/20 | 0.98 |
| ▸ | HTT | P42858 | 1/20 | 0.98 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.98 |
| ▸ | PDE3A | Q14432 | 1/20 | 0.98 |
| ▸ | AR | P10275 | 2/20 | 0.66 |
| ▸ | NR3C2 | P08235 | 4/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14656870 | 1.00 | LMNA (0.98) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| SCHEMBL353516 | 1.00 | LMNA (0.98) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL508890 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL94788 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL21497316 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL17517045 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL5330 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL16812894 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| Hydroxyprogesterone Caproate SCHEMBL14649335 | 0.99 | LMNA (1.00) | LMNANR3C1SMN1; SMN2HIF1APGR | |
| SCHEMBL17519899 | 0.97 | LMNA (0.96) | LMNANR3C1SMN1; SMN2HIF1APGR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-111892577-B | Compounds and methods for androgen receptor targeted degradation | 阿尔维纳斯运营股份有限公司 | 2023-07-07 | — | — | CN | claimed |
| CN-112262134-A | Cereblon ligand and bifunctional compound comprising same | 阿尔维纳斯运营股份有限公司 | 2021-01-22 | — | — | CN | claimed |
| US-20070292479-A1 | Film-shaped drug forms for use in the oral cavity (wafers) | BAYER SCHERING PHARMA AG (DE) | 2007-12-20 | — | — | US | claimed |
| CN-113348011-B | Method and apparatus for treating disease with biotherapeutic agents | 比奥拉治疗股份有限公司 | 2023-04-18 | — | — | CN | disclosed |
| CN-115504924-A | Hydrazino-pyrrolo compounds and methods for forming conjugates | 雷德伍德生物科技股份有限公司 | 2022-12-23 | — | — | CN | disclosed |
| CN-115297886-A | IL-7R alpha binding compounds | 麦地金公司 | 2022-11-04 | — | — | CN | disclosed |
| CN-115210250-A | Compositions and methods for regulatable regulation of transcription | 黑曜石疗法公司 | 2022-10-18 | — | — | CN | disclosed |
| CN-115175686-A | AKT inhibitors for enhancing persistence of chimeric T cells | H·李·莫菲特癌症中心研究所公司 | 2022-10-11 | — | — | CN | disclosed |
| CN-105744935-B | Hydrazino-pyrrolo compounds and methods for forming conjugates | 雷德伍德生物科技股份有限公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-115135308-A | Amorphous kinase inhibitor formulations and methods of use thereof | 德西费拉制药有限责任公司 | 2022-09-30 | — | — | CN | disclosed |
| CN-114728011-A | Preparations comprising steroid dimers and uses thereof in therapeutic agent delivery | 波纹疗法公司 | 2022-07-08 | — | — | CN | disclosed |
| CN-113286618-A | Antibody drug conjugates and uses for drug delivery of antibodies | 国立大学法人冈山大学 | 2021-08-20 | — | — | CN | disclosed |
| CN-113181112-A | Neuroactive steroid solutions and methods of their use | 萨奇治疗股份有限公司 | 2021-07-30 | — | — | CN | disclosed |
| CN-106794245-B | Combination therapy of tumor-targeted IL-2 variant immunocytokines and antibodies against human PD-L1 | 豪夫迈·罗氏有限公司 | 2021-06-01 | — | — | CN | disclosed |
| CN-112472814-A | Neuroactive steroid formulations and methods of treating central nervous system disorders | 萨奇治疗股份有限公司 | 2021-03-12 | — | — | CN | disclosed |
| CN-112262134-A | Cereblon ligand and bifunctional compound comprising same | 阿尔维纳斯运营股份有限公司 | 2021-01-22 | — | — | CN | disclosed |
| CN-112239209-A | Drug delivery through pore-modified mesoporous silica nanoparticles | 奈力生医股份有限公司 | 2021-01-19 | — | — | CN | disclosed |
| CN-111718354-A | MDM2 inhibitors and methods of treatment using the same | 密歇根大学董事会 | 2020-09-29 | — | — | CN | disclosed |
| CN-111529537-A | Methods of treating epilepsy or status epilepticus | 萨奇治疗股份有限公司 | 2020-08-14 | — | — | CN | disclosed |
| CN-111060687-A | GPC3 targeted therapeutic agents for administration to patients for whom GPC3 targeted therapeutic agent therapy is effective | 中外制药株式会社 | 2020-04-24 | — | — | CN | disclosed |